Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication

Table 3

Adverse events during eradication therapies.

Adverse event	EACM ()	EAC ()	value
Abdominal pain	9 (9.8%)	6 (6.5%)	0.419
Constipation	1 (1.1%)	2 (2.2%)	0.560
Diarrhea	11 (11.9%)	6 (6.5%)	0.203
Dizziness	7 (7.6%)	4 (4.3%)	0.315
Headache	6 (6.5%)	2 (2.2%)	0.148
Nausea/vomiting	10 (10.8%)	2 (2.2%)	0.017
Skin rash	0 (0%)	0 (0%)	—
Taste perversion	0 (0%)	0 (0%)	—

EACM group: 7-day esomeprazole/amoxicillin/clarithromycin/metronidazole therapy; EAC group: 7-day standard esomeprazole/amoxicillin/clarithromycin/triple therapy.